Trump Signs Executive Order to Boost Federal Research on Psychedelic Drugs
President Donald Trump signed an executive order on April 19, 2026, to promote federal medical research and clinical trials for certain psychedelic drugs. Key officials and guests, including FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr., attended the Oval Office signing.
Substrate placeholder — needs reviewPresident Donald Trump signed an executive order on Saturday, April 19, 2026, aiming to further federal medical research and clinical trials for certain psychedelic drugs, NBC News reported. FDA Commissioner Marty Makary was present in the Oval Office on April 19, 2026, during the signing. Health Secretary Robert F.
Kennedy Jr. was also present in the Oval Office on that date. Joe Rogan attended the event in the Oval Office as well. Americans for Ibogaine CEO W. Bryan Hubbard was in the Oval Office on April 19, 2026, for the occasion.
Former Navy SEAL Marcus Luttrell was present in the Oval Office on the same day. , Joe Rogan, Americans for Ibogaine CEO W.
The Trump administration has taken steps in the last week before April 21, 2026, to fast-track reviews of psychedelics, according to NBC News. These steps involve accelerating evaluations of psychedelics, which scientists are still assessing for safety and efficacy.
The administration's actions also include measures to widen access to some peptide injections in the same period. These developments on psychedelics and peptide injections represent recent policy moves by the administration as of April 21, 2026.
Key Facts
Story Timeline
4 events- 2026-04-19
President Donald Trump signed an executive order aiming to further federal medical research and clinical trials for certain psychedelic drugs.
1 sourceNBC News - 2026-04-19
FDA Commissioner Marty Makary, Health Secretary Robert F. Kennedy Jr., Joe Rogan, Americans for Ibogaine CEO W. Bryan Hubbard, and former Navy SEAL Marcus Luttrell were present and applauded in the Oval Office after the signing.
1 sourceNBC News - Last week before 2026-04-21
The Trump administration took steps to fast-track reviews of psychedelics.
1 sourceNBC News - Last week before 2026-04-21
The Trump administration took steps to widen access to some peptide injections.
1 sourceNBC News
Potential Impact
- 01
Potential acceleration of federal research and clinical trials for psychedelic drugs.
- 02
Expanded access to peptide injections for medical use.
- 03
Increased involvement of non-governmental figures like Joe Rogan in health policy discussions.
Transparency Panel
Related Stories
BBC NewsTrump Meets Advisers to Decide on Iran Ceasefire Extension
President Trump said he is holding a Situation Room meeting to make a final decision on a possible deal with Iran. The proposed agreement would extend the ceasefire by 60 days and reopen the Strait of Hormuz.
middleeasteye.netTrump to Decide on Iran Deal in Situation Room Meeting
President Trump said Friday he is heading into the Situation Room to make a final determination on a potential agreement with Iran. The proposed deal would reopen the Strait of Hormuz without tolls and require destruction of Iran's highly-enriched uranium.
realitytea.comTrump Says U.S. Will Lift Iran Naval Blockade After Nuclear and Hormuz Pledges
President Trump stated the U.S. will end its naval blockade of Iran once Tehran commits to forgoing nuclear weapons and opens the Strait of Hormuz to unrestricted shipping. The announcement came via Truth Social and a live statement.